Lumos Diagnostics has been awarded almost US$3.0m in US Government funding – as part of a milestone-bound deal worth > ...

Lumos Diagnostics Holdings Ltd (ASX:LDX) has received a significant boost to its development of FebriDx – a test which uses a ...

The BARDA funding will support studies to validate the Melbourne, Australia-headquartered firm's flagship FebriDx rapid host-response respiratory infection test in low-complexity settings and ...

Ph.D. The experiments were designed to meet the stringent requirements of the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) accreditation standards, ...